Investing.com -- US stock futures slipped lower Friday, with investors focusing on the release of key inflation data amid an uncertain economic outlook.
Here are some of the biggest premarket U.S. stock movers today:
-
Lululemon (NASDAQ:LULU) stock slid 11% after the sportswear maker provided downbeat annual forecasts as the broader apparel space battles an uneven consumer demand environment.
-
General Motors (NYSE:GM) slid 0.5% following a 7% decline in the previous session, while Ford (NYSE:F) slipped 0.6% after a 3.9% drop, as investors reacted to the Trump administration’s tariffs on auto imports.
-
Apple (NASDAQ:AAPL) stock fell 0.8% and Meta Platforms (NASDAQ:META) stock rose 0.1% after the Financial Times reported that the European Union is set to impose minimal fines on the tech giants under the Digital Markets Act next week in a bid to avoid worsening tensions with President Donald Trump.
-
Shell (LON:SHEL) (NYSE:SHEL) ADRs fell 0.3% after filings showed that U.S. activist hedge fund Elliott Management has taken a big short position in the energy major amid its campaign for more change at BP (NYSE:BP).
-
Applovin (NASDAQ:APP) stock rose 8.7%, bouncing after losses of over 20% in the previous session when a prominent short seller, Muddy Waters Research, issued a negative report on the app marketing firm.
-
Braze (NASDAQ:BRZE) stock rose 11% after the customer engagement software provider beat revenue expectations in the fourth quarter, with sales up 22.5% year on year.
-
Oxford Industries (NYSE:OXM) stock slumped 13% after the fashion conglomerate announced its full-year sales fell 3%, on the back of declines across its direct-to-consumer channel.
-
United States Steel Corporation (NYSE:X) rose 4.2% after Semafor reported that Nippon Steel and the U.S. steel producer are in active talks about a deal that would preserve their $14 billion merger and secure billions more in investments from the Japanese steelmaker into Rust Belt facilities.
-
CureVac NV (NASDAQ:CVAC) stock soared 14% after the European Patent Office declared a patent owned by the biopharmaceutical company valid, after a challenge from drugmaker BioNTech (NASDAQ:BNTX).